Pharmaceuticals

WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware

MIDDLETOWN, Del., Aug. 16, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus inMiddletown, Delaware. First announced in June 2021, this...

2022-08-17 01:47 6012

STANDIGM WINS GOLD AND BRONZE STEVIE® AWARDS IN 2022 INTERNATIONAL BUSINESS AWARDS®

Winners to Be Celebrated During Event in London on 15 October SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- Standigm was named the winner of a Gold Stevie® Award in the Pharmaceutical category and a Bronze Stevie® Award in the Computer Software category in The...

2022-08-16 20:30 3760

Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2022

JI'AN, China, Aug. 16, 2022 /PRNewswire/ -- Universe Pharmaceuticals INC (the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its unaudited financial results for the first six months of fiscal year 2022 endedMarch 31, 2022. Mr. Gang Lai, Chairman and ...

2022-08-16 20:00 3547

JIN-A02, A Novel 4th Generation EGFR TKI selected for the European Thoracic Oncology Platform - A First for Korean Pharma.

SEOUL, South Korea, Aug. 11, 2022 /PRNewswire/ -- J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented at the 2022 IASLC World Conference on Lung Cancer in Vienna, Austria on 8th August, at the official session "Overcomin...

2022-08-12 10:13 2414

Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers

SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient inAustralia in Phase I Study of ARB202, for the treatment of advanced gastrointestinal cancers patients. Globally, Arbele is the first company exploring...

2022-08-10 20:00 2545

Asieris Appoints Dr. Badrinath Konety to Scientific Advisory Board

An expert in genitourinary oncology, Dr. Konety brings deep academic insight, broad clinical expertise and a global network to help Asieris advance its innovative pipeline to serve patients worldwide. SHANGHAI, Aug. 10, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (stock code: 688176.SH), a glob...

2022-08-10 16:09 2368

Bridge Biotherapeutics Presents Promising Interim Clinical Study Results from Phase 1 Study of BBT-176 at WCLC 2022

* The study confirmed preliminary efficacy and safety of BBT-176 along with its treatment responses in advanced NSCLC patients * A patient with the C797S triple mutation showed up to 53 percent reduction in EGFR mutant allelic change VIENNA and SEONGNAM, South Korea, Aug. 9, 2022 /PRNewswire/...

2022-08-10 11:43 2775

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in China

SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 92 subjec...

2022-08-09 17:00 3248

Harbour BioMed to Announce 2022 Interim Results on August 31, 2022

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that it will report financial results for the first half year endedJune 30, 2022, on Wednesday, August 31, 2022. The Company will host an English virtual ...

2022-08-09 15:00 2600

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-004

SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene Biopharmaceutical ("Inmagene ") and HUTCHMED (China) Limited ("HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based inthe United States,...

2022-08-09 12:00 2423

BGI Ranks No. 1 among APAC and China Life Science Corporations for Seven Consecutive Years: 2022 Nature Index Annual Tables Revealed

SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- BGI has topped the Asia Pacific andChina life science corporate institution ranking table for the seventh year running, released in the 2022 Nature Index Annual Tables. With a 19 percent increase in its adjusted share metric, BGI ranked eighth among g...

2022-08-08 22:00 3202

PNAS Published Preclinical Results of Harbour BioMed's Next-Generation Fully Human Heavy-chain Antibody Porustobart

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the preclinical results of porustobart (HBM4003,or the HCAb 4003-2 in the research paper), a next-generation fully human heavy-chain antibody with a ...

2022-08-08 17:43 2755

The world's leading brand of fashionable colored masks officially launches on Amazon on August 8th from CSD, a professional disposable medical supplies manufacturer in Taiwan

TAIPEI, Aug. 8, 2022 /PRNewswire/ -- People dress according to mood, occasion, and necessity - and the mask, which inherently occupies half of the face, is an indispensable fashion accessory. On August 8th, COLO, a fashionable mask brand with colorful designs, will debut onAmazon

2022-08-08 13:04 2438

ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation

SHENZHEN, China, Aug. 7, 2022 /PRNewswire/ -- On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA").

2022-08-08 08:30 2232

Epigenic Therapeutics Raises $20 Million in Series Angel and Pre-A Funding to Advance Next Generation Gene Editing Therapy

SHANGHAI, Aug. 6, 2022 /PRNewswire/ -- Epigenic Therapeutics Co., Ltd., a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for wide variety of diseases, today announced it has secured$20 million in Series Angel a...

2022-08-07 07:00 4144

WeTrade Group Announced a Strategic Partnership with Jiqing Bio Company, to Exclusively Sell Monkeypox Test Kits and Antigen Tests

BEIJING, Aug. 5, 2022 /PRNewswire/ -- On 5th August, WeTrade Group Inc. ("Wetrade" or the "Company") (NASDAQ: WETG), an emerging growth company engaged in the business of providing software-as-a-services (SAAS) and cloud intelligent systems for micro-businesses, today announced a strategic partn...

2022-08-05 21:10 5585

United BioPharma's Study Reveals New Class of Monoclonal Antibody for Effective Relief of Urticaria Symptoms

New results demonstrate a newer class of anti-IgE antibody, UB-221, with superior neutralization, synthesis reduction, and durable relief in targeting allergic diseases  TAIPEI, Aug. 5, 2022 /PRNewswire/ -- United BioPharma (UBP) today announced their latest results featuring unprecedented and u...

2022-08-05 20:45 5414

Yiling's Lianhua Health Products Well-received: CICPE

SHIJIAZHUANG, China, Aug. 5, 2022 /PRNewswire/ -- As China's first national-level consumer expo and the largest such kind in theAsia-pacific region, the 2nd China International Consumer Products Expo (CICPE) attracted many audiences from different countries. And as the TOP 10 Chinese TCM Enterpr...

2022-08-05 15:54 7834

111 to Announce Second Quarter 2022 Unaudited Financial Results on August 25, 2022 - Conference Call to Follow

SHANGHAI, Aug. 5, 2022 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results...

2022-08-05 14:26 2542

ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022

-   STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation. -   STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022. SEOUL, South Korea, Aug. 3, 2022 /PRNewswire/ -- ST Pharm Co., Ltd. (237690:KOSDAQ) annou...

2022-08-03 20:00 2867
1 ... 140141142143144145146 ... 166

Week's Top Stories